eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Eliquis (apixaban) range of indications

ELIQUIS – an oral, direct factor Xa inhibitor – is indicated for:

  • Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II)1
  • Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
  • Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery1
Learn about ELIQUIS for
your patients with NVAF
Learn about ELIQUIS for
your patients with DVT / PE

Choose ELIQUIS for your patients with NVAF or DVT / PE

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

DVT = Deep Vein Thrombosis   
NVAF = Non-Valvular Atrial Fibrillation   
NYHA = New York Heart Association   
PE = Pulmonary Embolism   
TIA = Transient Ischaemic Attack   
VTE = Venous Thromboembolic Events


  1. ELIQUIS® (apixaban) Summary of Product Characteristics.